AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,023,460 | -11.3% | 122,160 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $3,408,595 | +39.1% | 120,360 | +12.8% | 0.00% | 0.0% |
| Q1 2023 | $2,449,980 | -26.7% | 106,660 | -10.4% | 0.00% | 0.0% |
| Q4 2022 | $3,343,205 | +1.1% | 119,060 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $3,308,000 | +29.1% | 116,960 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $2,562,000 | -23.8% | 115,560 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $3,364,000 | -12.4% | 115,560 | -1.0% | 0.00% | 0.0% |
| Q4 2021 | $3,838,000 | -32.1% | 116,760 | -4.7% | 0.00% | -50.0% |
| Q3 2021 | $5,652,000 | -25.7% | 122,460 | -11.3% | 0.00% | -20.0% |
| Q2 2021 | $7,608,000 | +3.5% | 138,060 | -3.0% | 0.01% | 0.0% |
| Q1 2021 | $7,351,000 | +20.7% | 142,360 | +1.3% | 0.01% | +25.0% |
| Q4 2020 | $6,090,000 | +23.8% | 140,560 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $4,920,000 | -33.2% | 140,560 | +2.1% | 0.00% | -33.3% |
| Q2 2020 | $7,362,000 | +77.4% | 137,660 | +17.7% | 0.01% | +50.0% |
| Q1 2020 | $4,150,000 | -24.7% | 116,960 | +1.3% | 0.00% | -33.3% |
| Q4 2019 | $5,513,000 | +71.1% | 115,460 | +16.1% | 0.01% | +100.0% |
| Q3 2019 | $3,223,000 | -33.9% | 99,460 | +1.7% | 0.00% | -40.0% |
| Q2 2019 | $4,876,000 | -24.2% | 97,760 | +2.5% | 0.01% | -28.6% |
| Q1 2019 | $6,431,000 | +51.2% | 95,360 | +3.4% | 0.01% | +40.0% |
| Q4 2018 | $4,254,000 | -38.5% | 92,260 | +2.8% | 0.01% | -37.5% |
| Q3 2018 | $6,922,000 | -8.4% | 89,760 | 0.0% | 0.01% | -11.1% |
| Q2 2018 | $7,560,000 | +6.2% | 89,760 | +3.1% | 0.01% | 0.0% |
| Q1 2018 | $7,120,000 | +77.8% | 87,060 | +24.3% | 0.01% | +125.0% |
| Q4 2017 | $4,005,000 | -12.4% | 70,060 | +2.3% | 0.00% | -20.0% |
| Q3 2017 | $4,570,000 | +34.1% | 68,460 | +3.3% | 0.01% | +25.0% |
| Q2 2017 | $3,409,000 | +5.4% | 66,260 | +19.7% | 0.00% | 0.0% |
| Q1 2017 | $3,233,000 | +44.7% | 55,360 | +3.4% | 0.00% | 0.0% |
| Q4 2016 | $2,235,000 | -21.0% | 53,560 | 0.0% | 0.00% | -20.0% |
| Q3 2016 | $2,829,000 | +41.9% | 53,560 | +12.6% | 0.01% | +66.7% |
| Q2 2016 | $1,993,000 | +38.4% | 47,560 | +29.4% | 0.00% | 0.0% |
| Q1 2016 | $1,440,000 | -23.7% | 36,760 | +26.5% | 0.00% | -40.0% |
| Q4 2015 | $1,887,000 | -8.0% | 29,060 | 0.0% | 0.01% | 0.0% |
| Q3 2015 | $2,051,000 | -26.9% | 29,060 | +15.0% | 0.01% | -28.6% |
| Q2 2015 | $2,807,000 | +22.2% | 25,260 | +3.7% | 0.01% | +16.7% |
| Q1 2015 | $2,297,000 | -15.8% | 24,360 | 0.0% | 0.01% | -40.0% |
| Q4 2014 | $2,729,000 | +188.8% | 24,360 | +58.2% | 0.01% | +150.0% |
| Q3 2014 | $945,000 | +33.9% | 15,400 | 0.0% | 0.00% | +33.3% |
| Q2 2014 | $706,000 | +185.8% | 15,400 | +144.4% | 0.00% | +200.0% |
| Q1 2014 | $247,000 | +118.6% | 6,300 | +34.0% | 0.00% | – |
| Q4 2013 | $113,000 | – | 4,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |